The U.S. Meals and Drug Administration mentioned on Friday it could take motion in opposition to telehealth supplier Hims & Hers for its $49 weight-loss tablet, together with limiting entry to the drug’s substances and referring the corporate to the Division of Justice for potential violations of federal regulation.
Federal motion to restrict the manufacturing of compounded medicine could be a win for Novo Nordisk, which has been dropping share within the weight-loss market to rival Eli Lilly and telehealth companies like Hims. Nevertheless, the FDA didn’t clarify whether or not it might rapidly halt the sale of Hims’ product, the most cost effective GLP-1 remedy on the U.S. market.
Shares of Hims fell 14.1% in after-hours commerce.
The FDA mentioned it plans to limit GLP-1 substances utilized in non-approved compounded medicine that corporations resembling Hims and different compounding pharmacies have marketed as alternate options to licensed remedies. The company cited issues over high quality, security and potential violations of federal regulation.
On Thursday, Reuters was first to report that Hims would start providing copies of Novo Nordisk’s new Wegovy tablet at an introductory value of $49 per thirty days, about $100 lower than the model title.
Novo Nordisk later mentioned it could take authorized motion in opposition to the telehealth firm over its plan to promote compounded copies of the drug.
The U.S. Division of Well being and Human Companies’ Basic Counsel, Mike Stuart, additionally mentioned on Friday he has referred Hims & Hers to the Division of Justice for investigation over potential violations.
Hims mentioned in an announcement that the corporate “has all the time operated with a deep dedication to the security and finest pursuits of customers and in compliance with relevant regulation.
“We’ve an extended historical past of efficiently working with regulators, and look ahead to persevering with to interact with the FDA to make sure protected entry to reasonably priced healthcare.”
A Lilly spokesperson mentioned the corporate applauded the FDA motion. “For years, compounders have been placing sufferers in danger by unlawfully mass-producing knockoff medicine utilizing substandard substances from illicit international suppliers and promoting them with out scientific proof that they are protected and even work. Sufferers deserve higher, and we look ahead to decisive motion by FDA, different regulators, and regulation enforcement.”
Compounding, through which pharmacies combine substances for specialised medicines or to repeat a drug however at completely different dosages, has flourished as People chase cheaper costs for medicine.
The apply is authorized beneath the Federal Meals, Drug and Beauty Act in sure circumstances, like when prescribed by a doctor to deal with affected person unintended effects or throughout a drug scarcity.
Hims’ compounded drug shouldn’t be FDA-approved and has not gone via scientific trials to show efficacy.
The FDA’s enforcement actions in opposition to Hims might embody sending a warning letter, pursuing a court docket injunction or conducting an administrative seizure of merchandise, mentioned Joanne Hawana, a member at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
The company would wish the assistance of the Justice Division to pursue an injunction, because it lacks unbiased litigation authority, Hawana mentioned.
The FDA’s statements counsel that “this announcement by Hims, to the federal government, is regarding sufficient that they determined they’ll escalate,” Hawana mentioned.
To this point, the FDA’s actions on weight-loss medicine have been restricted to warning letters despatched within the fall of 2025 to fight deceptive direct-to-consumer promoting and advertising and marketing.
Commissioner Marty Makary mentioned in an announcement on Friday that the company will “use all out there compliance and enforcement instruments inside its authorities to deal with unsubstantiated claims and related public well being issues.”
The well being regulator mentioned that, in promotional supplies, corporations can not declare that non-FDA-approved compounded merchandise are generic variations or the identical as medicine accredited by FDA.
It added that “additionally they can not state compounded medicine use the identical energetic ingredient because the FDA-approved medicine or that compounded medicine are clinically confirmed to provide outcomes for the affected person.”
